Four impact companies pitch live on TV March 17 with audience Q&A and voting. My Diabetes Health, rHEALTH, GigaWatt & BRG Therapeutics seek public investment inFour impact companies pitch live on TV March 17 with audience Q&A and voting. My Diabetes Health, rHEALTH, GigaWatt & BRG Therapeutics seek public investment in

Four Impact Companies to Pitch Live on National Television, Engaging Public in Investment Decisions

2026/03/04 16:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Four companies with distinct approaches to health and sustainability will present their investment opportunities during a live televised pitch event on March 17. The Superpowers for Good Live Pitch, produced by The Super Crowd, Inc., gives mission-driven businesses a national platform while engaging the public through real-time questions and voting.

The presenting companies—My Diabetes Health, rHEALTH, GigaWatt, and BRG Therapeutics—represent the breadth of impact investing, according to Léa Bouhelier-Gautreau, a Senior Investment Associate in Impact Investing at KingsCrowd. ‘Impact can be preventive health and patient education. It can be better diagnostics that shorten the time between suspicion and certainty. It can be energy infrastructure that helps households and businesses navigate electrification. And it can be the earliest stages of therapeutics,’ Bouhelier-Gautreau said.

My Diabetes Health focuses on insurance-covered telehealth diabetes education, reporting it has served 8,600 patients with an average 1.6-point A1C improvement. rHEALTH is developing a space-validated blood diagnostics platform intended for consumer and point-of-care use, with work connected to NASA and NIH. GigaWatt, an established energy business operating for 19 years, has generated more than $54 million in revenue since 2019. BRG Therapeutics is developing novel anticancer and antiviral therapeutics with a dual-action approach.

The event format emphasizes transparency and audience participation. Television viewers can submit questions for founders during the broadcast, with selected questions asked on-air. Viewers will also vote live for the SuperCrowd Award winner, while an expert judging panel selects a separate judges’ choice. ‘When you give viewers the chance to ask questions and hear answers live, you get closer to what investing actually feels like,’ said Sherwood Neiss, a General Partner at Crowdfund Capital Advisors.

Paul Lovejoy, a Principal Investment Advisor at Stakeholder Enterprise, noted that audience participation changes the broadcast’s dynamic. ‘Founders can sense the difference between a passive audience and an audience that’s doing diligence,’ Lovejoy said. ‘When questions come in from viewers and get asked on-air, it tends to elevate the conversation.’

Immediately following the broadcast, the production will host a private investor session via Zoom, open to anyone interested in investing in one or more of the companies. Registration is free at https://thesupercrowd.com/26q1pitch. The Superpowers for Good Live Pitch will air live on Roku and Amazon Fire TV via the e360tv Network, with additional distribution via social channels.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Four Impact Companies to Pitch Live on National Television, Engaging Public in Investment Decisions.

The post Four Impact Companies to Pitch Live on National Television, Engaging Public in Investment Decisions appeared first on citybuzz.

Market Opportunity
PUBLIC Logo
PUBLIC Price(PUBLIC)
$0.0151
$0.0151$0.0151
+0.13%
USD
PUBLIC (PUBLIC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09